UgoWork obtient un financement de 51 millions de dollars pour transformer l’industrie de la manutention grâce à ses solutions énergétiques avancées
31 juil. 2024 08h00 HE
|
UgoWork
QUÉBEC, 31 juill. 2024 (GLOBE NEWSWIRE) -- UgoWork™, un fournisseur de premier plan de solutions avancées de stockage d'énergie pour les véhicules de manutention, a annoncé aujourd'hui la...
UgoWork raises $51M to further transform material handling with its advanced energy solutions
31 juil. 2024 08h00 HE
|
UgoWork
QUEBEC, July 31, 2024 (GLOBE NEWSWIRE) -- UgoWork™, a premier provider of advanced energy storage solutions for material handling equipment, today announced the closing of $51M as part of its Series...
Memo Therapeutics increases Series C financing to CHF 45 million
07 mai 2024 07h00 HE
|
Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics increases Series C financing to CHF 45 million Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing...
Memo Therapeutics increases Series C financing to CHF 45 million
07 mai 2024 02h00 HE
|
Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics increases Series C financing to CHF 45 million Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing...
Diabeloop - Key Player in Therapeutic AI Applied to Insulin Delivery - Announces 70 Million Euros New Financing Round to Accelerate Its International Expansion
02 juin 2022 08h30 HE
|
Diabeloop SA
PARIS, June 02, 2022 (GLOBE NEWSWIRE) -- Diabeloop secures 70 million euros to pursue its solid and sustained growth strategy. The automated insulin delivery pioneer, develops machine-learning...
eureKARE participates in DNA Script’s $200 Million Series C Financing
04 janv. 2022 06h21 HE
|
eureKARE
eureKARE participates in DNA Script’s $200 Million Series C Financing Fundraise will accelerate commercial launch of revolutionary enzymatic DNA printing technology Luxembourg and Paris, France –...
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
27 mai 2021 07h00 HE
|
Pulmocide
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London, UK, 27 May 2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company...
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide
27 mai 2021 02h00 HE
|
Jeito Capital
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects Pulmocide as its fourth investment since launching the fundPulmocide is a late-stage biopharma...
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
27 mai 2021 02h00 HE
|
Pulmocide
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London, UK, 27 May 2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company...
AZTherapies Closes $26.3 Million Series C Preferred Equity Financing
17 oct. 2019 08h32 HE
|
AZTherapies, Inc.
BOSTON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced the closing of a $26.3 million Series C...